Impel NeuroPharma Strenthens Leadership Team With Appointment Of Lynn C. Gold As Senior Vice President Of Regulatory Affairs

SEATTLE, July 16, 2018 /PRNewswire/ -- Impel NeuroPharma, a Seattle-based, privately-held biotechnology company focused on therapies for the treatment of central nervous system (CNS) disorders, today announced that Lynn C. Gold, Ph.D., has joined the Company as the Senior Vice President of Regulatory Affairs. In this capacity, Gold has extensive oversight of regulatory strategy, agency communication and regulatory submissions. 

"We welcome Lynn to the team at such an exciting time for Impel, as we approach multiple clinical and regulatory milestones across our pipeline of four CNS products delivered via our novel, nasal POD™ device platform," said Jon Congleton, Chief Executive Officer of Impel NeuroPharma. "Lynn's broad expertise in regulatory affairs, coupled with her depth of knowledge in the 505(b)(2) pathway, from pre-IND to commercialization, will be a tremendous attribute for our Impel team."

Gold has distinguished herself with over 30 years of leadership in the pharmaceutical industry, including direct experience in virtually all regulatory aspects of pharmaceutical development. Her prior appointments include Camargo Pharmaceutical Services, LLC, where she was Vice President of Scientific and Regulatory Affairs, and Sonus Pharmaceuticals, where Gold served as Vice President of Research and Process Development. Other notable experience spanned engagements with Warner Chilcott Laboratories, Naryx Pharmaceuticals and Pharmacia and Upjohn.

"I am thrilled to be joining Impel in their mission to bring innovative solutions to people managing CNS disorders, "said Gold. "The drug-device combination products we are exploring stand to improve current treatment options, and my hope is to leverage my experience to help navigate the path towards realizing the full potential of the Impel pipeline. "

Gold has published in various peer-reviewed journals, including Regulatory Affairs and the American Association of Pharmaceutical Scientists (AAPS) Journal, in addition to presenting at major medical meetings, industry conferences, and universities. She is a member of AAPS, for which she has held leadership roles for the past 5 years, and the American Chemical Society (ACS) and Drug Information Association (DIA). Gold received her Bachelor of Science in chemistry from the State University of New York (SUNY) at Buffalo and her Ph.D. in organic photochemistry at the University of Rochester.

About Impel NeuroPharma
Impel NeuroPharma, Inc., is a privately-held, Seattle-based biotechnology company devoted to creating life-changing, innovative therapies for central nervous system (CNS) diseases. Impel NeuroPharma is currently investigating the potential benefits of INP104 (POD-DHE) for acute migraine headache, INP103 (POD-levodopa) for reversal of OFF episodes in Parkinson's disease, INP105 (POD-olanzapine) for acute agitation in schizophrenia and bipolar disorders as well as INP102 (POD-insulin) for Alzheimer's disease in a series of trials currently funded by the National Institutes of Health (NIH).

Impel's products utilize its novel, nasal drug delivery POD™ device technology, which is designed to deliver liquid or dry powder forms of drug to the upper nasal cavity in a consistent and predictable manner.

IMPEL, POD and the IMPEL Logo are trademarks of Impel NeuroPharma, Inc. To learn more about Impel NeuroPharma, please visit our website at http://impelnp.com.

Contact:
Melyssa Weible
Elixir Health Public Relations
Ph: (1) 201-723-5805
E: [email protected]

SOURCE Impel NeuroPharma

Related Links

http://impelnp.com